Therapeutic efficacy of entecavir and Anluohuaxianwan on 32 patients with hepatitis B-related cirrhosis

Objective To evaluate the efficacy of entecavir(ETV) combined with Anluohuaxianwan in treatment of patients with hepatitis B-related cirrhosis.Methods Totally 61 patients with hepatitis B-related cirrhosis were randomly assigned to a treatment group(n=32) and a control group(n=29).The treatment group received ETV 0.5 mg daily combined with Anluohuaxianwan 6 g daily,twice per day,for 12 months,while the control group received ETV 0.5 mg daily for 12 months.Results After 12 months of treatment,31 patients(96.8%) in the treatment group and 28(96.5%) in the control group achieved undetectable HBV DNA.HBeAg loss was observed in 4 of 13 HBeAg-positive patients in the treatment group and in 3 of 9 HBeAg-positive patients in the control group,respectively.Before treatment,Child-Pugh scores were 8.9±3.7 in the treatment group and 9.0±1.8 in the control group,respectively,and decreased significantly after treatment(5.0±0.1,7.4±1.2).After treatment,portal vein diameter and spleen thickness of the patients in the treatment group reduced more significantly than those of the patients in the control group(P 0.05),and serum parameters of liver fibrosis decreased significantly in the treatment group compared with the control group(P0.01).Conclusion ETV combined with Anluohuaxianwan achieves efficacy on the patients with hepatitis B-related cirrhosis.